BD (NYSE:BDX) announced today that it entered into a collaboration with Labcorp (NYSE:LH) to develop diagnostics.
The collaboration aims to create the framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.
Under the agreement, BD and Labcorp Drug Development will work together on flow cytometry-based CDx opportunities with pharmaceutical partners, bringing together capabilities that, according to a news release, comprise an end-to-end solution for CDx development.
The joint offering expected to come out of the partnership ranges from exploratory panel development to FDA approval of diagnostic and IVD kit manufacturing and distribution.
“Flow cytometry is a trusted and powerful tool for analyzing cells to better understand disease, and it has tremendous untapped potential as a companion diagnostic in on…